|
Re: flacid
|
3
|
Resverlogix Corp.
|
Jun 09, 2017 10:59AM
|
|
ESC 2017
|
3
|
Resverlogix Corp.
|
Jun 09, 2017 11:18AM
|
|
Re: Worst Communicating Company in History?
|
2
|
Zenith Epigenetics
|
Jun 10, 2017 04:31PM
|
|
Re: How much
|
2
|
Resverlogix Corp.
|
Jun 12, 2017 03:11PM
|
|
Re: Resverlax
|
2
|
Resverlogix Corp.
|
Jun 12, 2017 07:26PM
|
|
Another SGLT-2 inhibitor shows cardiovascular benefit in diabetics
|
6
|
Resverlogix Corp.
|
Jun 12, 2017 07:36PM
|
|
Re: Another SGLT-2 inhibitor shows cardiovascular benefit in diabetics
|
4
|
Resverlogix Corp.
|
Jun 12, 2017 08:00PM
|
|
Re: What now
|
5
|
Zenith Epigenetics
|
Jun 12, 2017 08:06PM
|
|
Re: Another SGLT-2 inhibitor shows cardiovascular benefit in diabetics
|
1
|
Resverlogix Corp.
|
Jun 12, 2017 08:24PM
|
|
Re: Corporate Update on Monday, June 19, 2017
|
1
|
Resverlogix Corp.
|
Jun 12, 2017 10:04PM
|
|
Anacetrapib/Reveal CETP Study results to be announced in August
|
3
|
Resverlogix Corp.
|
Jun 13, 2017 10:43AM
|
|
Re: What now
|
2
|
Zenith Epigenetics
|
Jun 13, 2017 01:26PM
|
|
biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders
|
|
BIOASIS TECHNOLOGIES INC
|
Jun 14, 2017 10:08AM
|
|
Re: biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jun 14, 2017 10:36AM
|
|
Re: Fabry trial news, Halifax and Alberta's Children't Hospital slated....
|
4
|
Resverlogix Corp.
|
Jun 14, 2017 10:44AM
|
|
Epizyme shares slump as cancer drug data update disappoints
|
1
|
Zenith Epigenetics
|
Jun 14, 2017 11:16AM
|
|
Will Phase 2a Renal trial start tomorrow?
|
6
|
Resverlogix Corp.
|
Jun 14, 2017 10:43PM
|
|
Will there be an anniversary gift?
|
2
|
Zenith Epigenetics
|
Jun 14, 2017 10:46PM
|
|
biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
|
|
BIOASIS TECHNOLOGIES INC
|
Jun 15, 2017 09:56AM
|
|
Re: biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
|
1
|
BIOASIS TECHNOLOGIES INC
|
Jun 15, 2017 10:02AM
|
